Large-scale purification of a murine antimelanoma monoclonal antibody

1986 ◽  
Vol 4 (4) ◽  
pp. 189-204 ◽  
Author(s):  
Shwu-Maan Lee ◽  
Mark E. Gustafson ◽  
Dana J. Pickle ◽  
Michael C. Flickinger ◽  
Gary M. Muschik ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Large Scale

scholarly journals Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Yuan Li ◽  
Hongliu Ye ◽  
Meng Liu ◽  
Suquan Song ◽  
Jin Chen ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Large Scale ◽  
Operation Time ◽  
Reference Method ◽  
Antibody Detection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antibody Concentration

Abstract Background H7 subtype avian influenza has caused great concern in the global poultry industry and public health. The conventional serological subtype-specific diagnostics is implemented by hemagglutination inhibition (HI) assay despite lengthy operation time. In this study, an efficient, rapid and high-throughput competitive enzyme-linked immunosorbent assay (cELISA) was developed for detection of antibodies against H7 avian influenza virus (AIV) based on a novel monoclonal antibody specific to the hemagglutinin (HA) protein of H7 AIV. Results The reaction parameters including antigen coating concentration, monoclonal antibody concentration and serum dilution ratio were optimized for H7 antibody detection. The specificity of the cELISA was tested using antisera against H1 ~ H9, H11 ~ H14 AIVs and other avian viruses. The selected cut-off values of inhibition rates for chicken, duck and peacock sera were 30.11, 26.85 and 45.66% by receiver-operating characteristic (ROC) curve analysis, respectively. With HI test as the reference method, the minimum detection limits for chicken, duck and peacock positive serum reached 20, 21 and 2− 1 HI titer, respectively. Compared to HI test, the diagnostic accuracy reached 100, 98.6, and 99.3% for chicken, duck and peacock by testing a total of 400 clinical serum samples, respectively. Conclusions In summary, the cELISA assay developed in this study provided a reliable, specific, sensitive and species-independent serological technique for rapid detection of H7 antibody, which was applicable for large-scale serological surveillance and vaccination efficacy evaluation programs.

A safe, effective, and facility compatible cleaning in place procedure for affinity resin in large-scale monoclonal antibody purification

2013 ◽  
Vol 1308 ◽  
pp. 86-95 ◽  
Author(s):  
Lu Wang ◽  
Jill Dembecki ◽  
Neil E. Jaffe ◽  
Brian W. O’Mara ◽  
Hui Cai ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Large Scale ◽  
Antibody Purification ◽  
Affinity Resin

scholarly journals Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines

2020 ◽  
Vol 2020 ◽  
pp. 1-14
Author(s):  
Qian Qian ◽  
Changping Wu ◽  
Jianping Chen ◽  
Weibing Wang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Monoclonal Antibody ◽  
Cell Lines ◽  
Western Blotting ◽  
Large Scale ◽  
Expression Level ◽  
Survival Duration ◽  
Great Promise ◽  
Clinical Response Rate ◽  
Liver Hepatocellular Carcinoma

Background. Despite the large-scale clinical application of programmed death-ligand 1 (PD-L1) monoclonal antibody, reduction in its clinical response rate has become a gradual problem. As such, use of PD-L1 monoclonal antibody in combination with other anticarcinoma drugs has been the main strategy in improving its efficacy. Interleukin 10 (IL10) is a recognized inflammatory and immunosuppressive factor. Previous studies have suggested that there is a link between PD-L1 and IL10. Objective. This study was aimed at clarifying the relationship between PD-L1 and IL10 in liver hepatocellular carcinoma (LIHC) and whether IL10 enhances the efficacy of PD-L1 inhibitor. Methods. Expression levels of PD-L1 and IL10 in carcinoma and adjacent tissues were tested by immunochemistry, Western blotting, and RT-PCR. Survival duration and follow-up data of each patient were recorded. LIHC cell lines Bel7405 and MHCC 97-H were used for in vitro experiments. Exogenous IL10 and anti-IL10 were added to cell supernatant. Expression level of PD-L1 in the LIHC cell lines was determined using Western blotting and ELISA. CCK8 and transwell assays were adopted to examine the effect of PD-L1 combined with IL10 on proliferation, invasion, and metastasis of LIHC cells. Results. The survival period of patients with low expression of IL10 was longer than that of patients with high expression (P=0.01). Overexpression of PD-L1 increased the IL10 and Met levels in LIHC tissues and cell lines. IL10 downregulated the expression level of PD-L1 and enhanced the efficacy of crizotinib via the Met signaling pathway in the LIHC cells. Conclusions. A combination of IL10 and PD-L1 inhibitor holds great promise as an effective treatment for LIHC.

Large-scale purification and preliminary structural studies of Mac 182, A gibberellin-binding monoclonal antibody

1992 ◽  
Vol 31 (10) ◽  
pp. 3337-3339 ◽  
Author(s):  
Joan E. Nester-Hudson ◽  
Michael H. Beale ◽  
Jake Macmillan
Keyword(s):  
Monoclonal Antibody ◽  
Large Scale ◽  
Structural Studies

scholarly journals Emergency department use of monoclonal antibody therapy in high risk COVID positive patients

2021 ◽  
Vol 10 (2) ◽  
pp. 38
Author(s):  
Andrew R. Barbera ◽  
Kayla Wilson ◽  
James D. Melton III ◽  
Fred Blind ◽  
Donna M. Bhisitkul ◽  
...  
Keyword(s):  
Emergency Department ◽  
Monoclonal Antibody ◽  
High Risk ◽  
Large Scale ◽  
Best Practice ◽  
Antibody Therapy ◽  
Monoclonal Antibody Therapy ◽  
Regional Health ◽  
Staff Members ◽  
Medical Centers

Background: There have been many perceived barriers to the implementation of the mass use of monoclonal antibody therapy following the Food and Drug Administration’s Emergency Use Authorization in November 2020. These barriers include identifying eligible patients, physical resources including trained staff members, space, and materials for the administration away from others to reduce transmission, and cost of the resources. However, Lakeland Regional Health was able to create a safe and efficient protocol to administer Bamlanivimab in the treatment of high risk COVID positive patients and initiate this proposed pathway within 24 hours of receipt of the first shipment of medication.Methods: Critical to the development and success of this protocol was a multi-disciplinary approach focused on identifying and utilizing preexisting resources to ensure safe and efficient administration of this treatment to as many eligible patients as possible. Another crucial aspect was the utilization of the emergency department providers for identifying high risk eligible patients and as a safe and effective treatment setting.Results: This article is intended to demonstrate a best practice pathway to identify and administer Bamlanivimab, or similar treatments, and will not discuss outcomes or efficacy of the medication. To date Lakeland Regional Health has successfully treated over 1,000 high risk COVID-19 positive patients within our community.Conclusions: By identifying and utilizing similar resources and pathways available at individual medical centers, it is possible to safely and efficiently treat high risk COVID positive patients with monoclonal antibody therapy on a large scale.

scholarly journals Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

2020 ◽  
Author(s):  
Yuan Li ◽  
Hongliu Ye ◽  
Meng Liu ◽  
Suquan Song ◽  
Jin Chen ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Large Scale ◽  
Operation Time ◽  
Reference Method ◽  
Antibody Detection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antibody Concentration

Abstract Background: H7 subtype avian influenza have caused great concern in the global poultry industry and public health. The conventional serological subtype-specific diagnostics is implemented by hemagglutination inhibition (HI) assay despite lengthy operation time. In this study, an efficient, rapid and high-throughput competitive enzyme-linked immunosorbent assay (cELISA) was developed for detection of antibodies against H7 avian influenza virus (AIV) based on a novel monoclonal antibody specific to the hemagglutinin (HA) protein of H7 AIV. Results: The reaction parameters including antigen coating concentration, monoclonal antibody concentration and serum dilution ratio were optimized for H7 antibody detection. The specificity of the cELISA was tested using antisera against H1~H9, H11~H14 AIVs and other avian viruses. The selected cut-off values of inhibition rates for chicken, duck and peacock sera were 30.11%, 26.85% and 45.66% by receiver-operating characteristic (ROC) curve analysis, respectively. With HI test as the reference method, the minimum detection limits for chicken, duck and peacock positive serum reached 2 0 , 2 1 and 2 -1 HI titer, respectively. Compared to HI test, the diagnostic accuracy reached 100%, 98.6%, and 99.3% for chicken, duck and peacock by testing a total of 400 clinical serum samples, respectively. Conclusions: In summary, the cELISA assay developed in this study provided a reliable, specific, sensitive and species-independent serological technique for rapid detection of H7 antibody, which was applicable for large-scale serological surveillance and vaccination efficacy evaluation programs.

A monoclonal antibody for large-scale purification of human leukocyte interferon

Nature ◽  
1980 ◽  
Vol 285 (5765) ◽  
pp. 446-450 ◽  
Author(s):  
David S. Secher ◽  
Derek C. Burke
Keyword(s):  
Monoclonal Antibody ◽  
Large Scale ◽  
Human Leukocyte ◽  
Human Leukocyte Interferon

scholarly journals Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

2020 ◽  
Author(s):  
Yuan Li ◽  
Hongliu Ye ◽  
Meng Liu ◽  
Suquan Song ◽  
Jin Chen ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Large Scale ◽  
Operation Time ◽  
Reference Method ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antibody Concentration ◽  
Roc Curve Analysis

Abstract Background Since 2013, avian influenza outbreaks in poultry especially the H7 subtype have been causing a major concern for poultry industry and public health in China. The conventional serological subtype-specific diagnostics is implemented by hemagglutination inhibition (HI) assay despite lengthy operation time. An efficient, rapid and high-throughput competitive enzyme-linked immunosorbent assay (cELISA) was developed for detection of antibodies against H7 avian influenza virus (AIV) based on a novel monoclonal antibody specific to the hemagglutinin (HA) protein of H7 AIV. Results The reaction parameters of antigen coating concentration, monoclonal antibody concentration and serum dilution ratio were optimized for detection of H7 antibodies in chicken, ducks and peacocks sera. The specificity of the cELISA was tested using antisera against H1 ~ H9, H11 ~ H14 AIVs and other avian viruses. The selected cut-off values of inhibition rates for chicken, duck and peacock sera were 30.11%, 26.85% and 45.66% by receiver-operating characteristic (ROC) curve analysis, respectively. With the HI test as a reference method, the minimum detection limits for chicken, duck and peacock positive serum reached 20, 21 and 2− 1 HI titer, respectively. Compared to the HI test, the diagnostic accuracy reached 100%, 98.6%, and 99.3% for chicken, duck and peacock by testing a total of 400 clinical serum samples, respectively. Conclusions In summary, the cELISA immunoassay for rapid detection of H7 antibody in sera from different avian species was highly specific, extremely sensitive and might be exploited for the large-scale serological diagnosis of H7 AIVs.

Sign in / Sign up

Export Citation Format

Share Document